A Phase 2/3 interventional study of PRX-102 1 mg/kg every 2 weeks and PRX-102 2 mg/kg every 4 weeks in Fabry Disease, sponsored by Chiesi Farmaceutici S.p.A.. Recruiting at 10 sites in Japan. Open to participants aged 13 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-03-18.
Sponsored by Chiesi Farmaceutici S.p.A. · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing pegunigalsidase alfa in Fabry Disease — 2 open to participants now, 2 under way, 2 of them phase 3. pegunigalsidase alfa · Fabry Disease.
Among the 10 studies testing pegunigalsidase alfa in Fabry Disease, this one is the 8th largest by planned enrollment, is the only one that started in 2023, is one of 2 in phase 2/3, and was the 9th registered.
244 studies on the registry are indexed under Fabry Disease; 54 are open to participants now.
Browse Fabry Disease studies →2 of the 10 studies testing pegunigalsidase alfa in Fabry Disease are open now, in 7 countries. Recruiting first, the newest first:
Chiesi Farmaceutici S.p.A. · Sites in United States, Austria, France and 3 more countries
Ages 2–17
By country, each count listing its studies:
pegunigalsidase alfa: first FDA approval 2023 (ELFABRIO), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 44 Fabry Disease studies recruiting now, 31 (70%) set no upper age limit and 11 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.
This study: 13 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 8
First in 2012; this study’s year is marked. 1 started in 2023.
This study's planned enrollment of 16 is below the median of 22 across 108 interventional studies indexed under Fabry Disease.
Median enrollment 22 across the 10 interventional studies. Of the 7 that completed or were terminated, 6 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 10 have an industry lead sponsor. The 2 most frequent:
Chiesi Farmaceutici S.p.A. is the lead sponsor of 185 studies on the registry; 22 are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 11 (61%) have results posted.
10 studies in Fabry Disease by Chiesi Farmaceutici S.p.A.: 5 open now, 5 under way, 2 of them phase 3. Of 4 finished, 1 (25%) have results posted.
Among the 10 studies in Fabry Disease by Chiesi Farmaceutici S.p.A., this one is the only one that started in 2023, is one of 2 in phase 2/3, and was the 6th registered.
Chiesi Farmaceutici S.p.A.’s Fabry Disease studies by the year they started, since 2018.
1 of the studies testing pegunigalsidase alfa in Fabry Disease that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05710692Phase 3Chiesi Farmaceutici S.p.A.Study to Evaluate the Safety, PK, PD, and Efficacy of PRX-102 in Japanese Patients With Fabry Disease | 2027-10 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies testing pegunigalsidase alfa in Fabry Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Chiesi Farmaceutici S.p.A.’s 10 in Fabry Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The aim of this study is to evaluate the safety and efficacy of pegunigalsidase alfa in Japanese patients (adults and adolescents) affected by Fabry disease. It is planned of a total of approximately 16 male and female Fabry disease patients between the ages of 13 and 70 years to be part of the study. The study is conducted in Japan.
Investigators are doing this study to find out if treatment with pegunigalsidase alfa will prevent or reduce the development of health problems caused by Fabry disease and thereby improve patients' health and quality of life.
pegunigalsidase alfa (PRX-102) is a drug made using genetic engineering techniques and manufactured using cultured tobacco cells. It is given by intravenous infusion every 2 weeks, at a dosage of 1 milligram per kilogram (mg/kg) of body weight.
The study consists of a main study that is divided into two stages, each of which will last one year, followed by an optional extension study. In stage II of main study and in the optional extension study, the participants may receive PRX-102 intravenous infusion every 2 weeks, at a dosage of 1 milligram per kilogram (mg/kg) of body weight or every 4 weeks at a dosage of 2 milligrams per kilogram (mg/kg) of body weight.
There are three groups (cohorts) in this study, with adults enrolled in either Cohort A or B and adolescents in Cohort C. Whether an adult is assigned to Cohort A or Cohort B depends on their kidney function and treatment history.
This study will start with a screening visit of up to 6 weeks. It will be followed up by infusion visits every 2 weeks or 4 weeks. For subjects not continuing in the extension stage, a follow-up call is to be made 30 days after the last study drug infusion.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
A documented diagnosis of Fabry disease, as determined by the following:
A female subject (including an adolescent in Cohort C, if applicable) must meet one of the following criteria:
If of , she must:
Agree to use one of the following highly reliable methods of from the day of the signature until 30 days after the last infusion received. The following methods are acceptable:
Be of non-childbearing potential, defined as one of the following:
Additional inclusion criteria for subjects in Cohort A
For subjects enrolled in Cohort A, these specific inclusion criteria, in addition to those above, apply:
Additional inclusion criterion for subjects in Cohort B
For subjects enrolled in Cohort B, this specific inclusion criterion, in addition to those above, applies:
- Aged ≥18 to ≤70 years
Additional inclusion criteria for subjects in Cohort C
For subjects enrolled in Cohort C, these specific inclusion criteria, in addition to those above, apply:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PRX-102 1 mg/kg every 2 weeks or PRX-102 2 mg/kg every 4 weeks (available only in the optional extension part)
Drug: PRX-102 1 mg/kg every 2 weeks · Drug: PRX-102 2 mg/kg every 4 weeks
Drug page: Pegunigalsidase alfa
PRX-102 1 mg/kg every 2 weeks
Also known as: pegunigalsidase alfa, Recombinant human alpha galactosidase-A
Drug page: Pegunigalsidase alfa
PRX-102 2 mg/kg every 4 weeks
Also known as: pegunigalsidase alfa, Recombinant human alpha galactosidase-A
Incidence of Treatment Emergent Adverse Events (TEAEs)
Time frame: 12 Months, 24 Months and through study completion (an average of 4.5 years)
Incidence of Infusion Related Reactions (IRRs)
Time frame: 12 Months, 24 Months and through study completion (an average of 4.5 years)
Incidence of Injection site reactions (ISRs)
Time frame: 12 Months, 24 Months and through study completion (an average of 4.5 years)
Change of laboratory tests' results
Time frame: 12 Months, 24 Months and through study completion (an average of 4.5 years)
Change in in body weight in kilograms
Time frame: 12 Months, 24 Months and through study completion (an average of 4.5 years)
Change in height in centimeters
Time frame: 12 Months, 24 Months and through study completion (an average of 4.5 years)
Change in Tanner stage
Tanner Staging of Sexual Development will be used to assess sexual development (i.e. breast development (B1 to B5) and pubic hair development (Ph-1 to Ph-5) in females and pubic hair and genetical development (G1-G5) in males.
Time frame: 12 Months, 24 Months and through study completion (an average of 4.5 years)
Change from baseline of 12-lead ECG quantitative parameters: Mean Heart Rate, PR Interval, QRS Duration, QT Interval, QTc Interval, and ST Segment
Quantitative ECG parameters will be summarized by cohort and overall
Time frame: 12 Months, 24 Months and through study completion (an average of 4.5 years)
Incidence of treatment-emergent Anti-Drug Antibodies (ADAs)
Time frame: 12 Months, 24 Months and through study completion (an average of 4.5 years)
ADA status change from baseline
Time frame: 12 Months, 24 Months and through study completion (an average of 4.5 years)
Incidence of premedication use at each visit and change of infusion premedications from baseline
Time frame: 12 Months, 24 Months and through study completion (an average of 4.5 years)
Change from baseline of Maximum plasma concentration (Cmax), pharmacokinetic parameter
Time frame: Assessments will be done over three two-week periods, starting at Baseline (Week 0), V7 (Week 12), and V27 (Week 52)
Change from baseline of Time to maximum plasma concentration (tmax), pharmacokinetic parameter
Time frame: Assessments will be done over three two-week periods, starting at Baseline (Week 0), V7 (Week 12), and V27 (Week 52)
Change from baseline of Area under the plasma concentration-time curve from time 0 to time t (AUC0 t), pharmacokinetic parameter
Time frame: Assessments will be done over three two-week periods, starting at Baseline (Week 0), V7 (Week 12), and V27 (Week 52)
Change from baseline of Area under the curve from time 0 to 2 weeks (AUC0-2wk), pharmacokinetic parameter
Time frame: Assessments will be done over three two-week periods, starting at Baseline (Week 0), V7 (Week 12), and V27 (Week 52)
Change from baseline of Area under the curve from time 0 to infinity (AUC0-∞), pharmacokinetic parameter
Time frame: Assessments will be done over three two-week periods, starting at Baseline (Week 0), V7 (Week 12), and V27 (Week 52)
Change from baseline of Terminal half-life (t1/2), pharmacokinetic parameter
Time frame: Assessments will be done over three two-week periods, starting at Baseline (Week 0), V7 (Week 12), and V27 (Week 52)
Change from baseline of Area under the curve over a dosing interval (AUCτ), pharmacokinetic parameter
Time frame: Assessments will be done over three two-week periods, starting at Baseline (Week 0), V7 (Week 12), and V27 (Week 52)
Change from baseline of Observed drug concentration at the end of the dosing interval (Cτ), pharmacokinetic parameter
Time frame: Assessments will be done over three two-week periods, starting at Baseline (Week 0), V7 (Week 12), and V27 (Week 52)
Change from baseline of Clearance (Cl), pharmacokinetic parameter
Time frame: Assessments will be done over three two-week periods, starting at Baseline (Week 0), V7 (Week 12), and V27 (Week 52)
Change from baseline of Volume of distribution (Vz), pharmacokinetic parameters
Time frame: Assessments will be done over three two-week periods, starting at Baseline (Week 0), V7 (Week 12), and V27 (Week 52)
Change in eGFR
Time frame: 12 Months, 24 Months and through study completion (an average of 4.5 years)
Change in annualized eGFR slope
Time frame: 12 Months, 24 Months and through study completion (an average of 4.5 years)
Change in urine albumin levels
Time frame: 12 Months, 24 Months and through study completion (an average of 4.5 years)
Change in urine protein levels
Time frame: 12 Months, 24 Months and through study completion (an average of 4.5 years)
Incidence of changes in echocardiogram results
Systolic and diastolic heart function and structure is assessed by ultrasound of the heart. Echocardiogram parameters include left ventricular mass index (LVMi), ejection fraction, fractional shortening, left ventricular mass, valve abnormalities and thickness.
Time frame: 12 Months, 24 Months and through study completion (an average of 4.5 years)
Incidence of changes in Holter ECG
Time frame: 12 Months, 24 Months and through study completion (an average of 4.5 years)
Change of cardiac biomarkers
Time frame: 12 Months, 24 Months and through study completion (an average of 4.5 years)
Adults only: Response of the heart to external stress induced by exercise measured with Stress test (Bruce protocol)
Qualitative evaluation (yes/no) of symptoms (chest pain, shortness of breath, dizziness, palpitations, and other) and the overall impression: normal stress test (yes/no) will be summarized. For overall impression only, a shift from baseline will be presented: normal stress test (yes / no).
Time frame: 12 Months, 24 Months and through study completion (an average of 4.5 years)
Adults only: change of Cardiac MRI
Time frame: 12 Months, 24 Months and through study completion (an average of 4.5 years)
Adults only: change of Brain MRI
Time frame: 12 Months, 24 Months and through study completion (an average of 4.5 years)
Change in plasma level of Gb3 concentration (nM)
Time frame: 12 Months, 24 Months and through study completion (an average of 4.5 years)
Change in plasma level of lyso-Gb3 (nM)
Time frame: 12 Months, 24 Months and through study completion (an average of 4.5 years)
Change in urine level of lyso-Gb3 (nM)
Time frame: 12 Months, 24 Months and through study completion (an average of 4.5 years)
Change from baseline of Mainz Severity Score Index (MSSI) scores
Domains (general, neurological, cardiovascular, renal dysfunction)
Time frame: 12 Months, 24 Months and at the end of study
Incidence of change from baseline in the number of different pain medications
Time frame: 12 Months, 24 Months and at the end of study
Incidence of Fabry Clinical Events
FCEs are classified into four categories: renal, cardiac, cerebrovascular and death due to non-cardiac reasons
Time frame: 12 Months, 24 Months and at the end of study
Adults only: change in Gastrointestinal Symptom Rating Scale (GSRS) scores
To measure common symptoms of gastrointestinal disorders.
Time frame: 12 Months, 24 Months and at the end of study
Adults only: change in Brief Pain Inventory - Short Form (BPI-SF) scores
Time frame: 12 Months, 24 Months and at the end of study
Adults only: change of quality of life assessed using EQ-5D-5L questionnaire
Time frame: 12 Months, 24 Months and at the end of study
Cohort C only: Change in Gastrointestinal Symptoms (PedsQL-GI) Questionnaire scores
To measure common symptoms of gastrointestinal disorders.
Time frame: 12 Months, 24 Months and at the end of study
Cohort C only: change in Fabry-Specific Pediatric Health and Pain Questionnaire (FPHPQ) scores
Time frame: 12 Months, 24 Months and at the end of study
Cohort C only: change in PedsQL Pediatric Pain Questionnaire (PedsQL-PPQ) scores
Time frame: 12 Months, 24 Months and at the end of study
Cohort C only: change of quality of life assessed using EQ-5D-Y Questionnaire
Time frame: 12 Months, 24 Months and at the end of study
Not enrolling at this site.
Started Aug 2023 (actual). Primary completion is estimated for Oct 2027, 50 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pegunigalsidase alfa